vTv Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:VTVT   3:59:42 PM EDT
2.34
+0.07 (+3.08%)
Products, Regulatory

vTv Therapeutics Announces Topline Results Of Phase 2 Elevage Study Of Azeliragon In Patients With Mild Alzheimer’S Disease And Type 2 Diabetes

Published: 12/15/2020 23:25 GMT
vTv Therapeutics Inc - Ordinary Shares - Class A (VTVT) - Vtv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients With Mild Alzheimer’s Disease and Type 2 Diabetes.
Vtv Therapeutics - Phase 2 Elevage Study of Azeliragon in People With Mild Alzheimer's Disease and Type 2 Diabetes Did Not Meet Its Primary Objective.
Vtv Therapeutics- Azeliragon Was Generally Well-tolerated With Similar Incidences of Treatment-emergent Adverse Events Overall and by System Organ Class.